enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Rhea-AI Summary

enVVeno Medical (NASDAQ:NVNO) announced that CEO Robert Berman participated in the Virtual Investor “Why Now” on-demand conference, where he outlined the company’s investment opportunity and the unmet need in treating severe Deep Venous Insufficiency (DVI).

Berman discussed enVVeno’s non-surgical replacement venous valve, enVVe, and the recent FDA IDE approval for a U.S. pivotal study of the device. The TAVVE pivotal trial is expected to start in the fourth quarter of 2026 and enroll about 230 patients across up to 40 U.S. sites, as a key step toward potential regulatory approval of the enVVe System. A video webcast of the presentation is available for on-demand viewing. enVVeno is a late clinical-stage medical device company focused on bioprosthetic solutions for deep venous disease.

Market Context

The active S-3, filed August 21, 2026 and not yet effective, adds capital-raising context to the con...

Analysis

The active S-3, filed August 21, 2026 and not yet effective, adds capital-raising context to the conference update. A director’s sale of 140 shares was also recorded; investors can monitor execution of the clinical program.

Key Figures

Trial enrollment: approximately 230 patients Clinical sites: up to 40 U.S. clinical sites Trial commencement: fourth quarter of 2026

3 metrics

Trial enrollment approximately 230 patients TAVVE pivotal trial

Clinical sites up to 40 U.S. clinical sites TAVVE pivotal trial

Trial commencement fourth quarter of 2026 TAVVE pivotal trial

Historical Context

5 past events · Latest: Aug 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 04	Health economic study	Positive	+4.2%	Study projected healthcare savings, fewer ulcers, improved QALYs, and broader system-wide economic benefits.
Jul 31	2Q26 earnings report	Negative	-0.3%	Quarterly loss and increased expected cash burn accompanied FDA IDE progress toward the pivotal trial.
Jul 15	Investor presentation	Positive	-1.3%	Management highlighted patent issuance and progress toward an FDA-approved pivotal venous valve trial.
Jul 07	Patent issuance	Positive	-0.7%	U.S. patent covered core enVVe valve, support frame, crimping, and delivery system components.
Jun 22	Webinar presentation	Positive	+5.0%	Company scheduled a presentation covering FDA IDE approval and plans for its pivotal trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive announcements produced mixed reactions, with three divergences and two alignments.

Key Terms

deep venous insufficiency, ide, pivotal trial, bioprosthetic

4 terms

deep venous insufficiency medical

"severe Deep Venous Insufficiency (DVI) and the substantial market opportunity"

Deep venous insufficiency is a condition where the one-way valves in the deep veins of the legs fail, letting blood pool or flow backward instead of returning efficiently to the heart — imagine valves in a pipe that no longer close properly. For investors, it matters because it drives demand for treatments, diagnostic tests and medical devices, influences healthcare spending and reimbursement trends, and can affect the commercial prospects and regulatory risk for companies developing related therapies.

ide regulatory

"recent achievement of the FDA IDE approval for a U.S. pivotal study"

An IDE (Investigational Device Exemption) is a regulatory permission that allows a company to test an unapproved medical device in human clinical trials to gather safety and effectiveness data. Think of it as a temporary road permit for a new product: getting the IDE moves a technology from concept toward approval and market access, which can reduce uncertainty and increase value for investors, while delays or denials raise development risk and potential costs.

pivotal trial medical

"The TAVVE pivotal trial is expected to commence in the fourth quarter of 2026"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

bioprosthetic medical

"a first-in-class bioprosthetic venous valve designed to address"

A bioprosthetic is a medical implant made from biological tissues—often animal or human-derived—used to replace or support body parts like heart valves or joints. Think of it as a natural-material replacement part that mimics living tissue; it matters to investors because its performance, durability, manufacturing complexity, and regulatory approval drive clinical adoption, repeat procedures, reimbursement and long-term revenue potential for companies that develop or sell these devices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Video Webcast Now Available Here

IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference.

For the event, Mr. Berman highlighted the Company's investment opportunity, including the significant unmet need for effective treatment options for patients with severe Deep Venous Insufficiency (DVI) and the substantial market opportunity for Company's non-surgical replacement venous valve called enVVe. He also discussed the Company's recent achievement of the FDA IDE approval for a U.S. pivotal study evaluating enVVe, an important regulatory catalyst for the Company. The TAVVE pivotal trial is expected to commence in the fourth quarter of 2026 and ultimately enroll approximately 230 patients across up to 40 U.S. clinical sites. The trial represents an important next step towards potential regulatory approval of the enVVe System, a first-in-class bioprosthetic venous valve designed to address the underlying cause of severe DVI, and a significant potential value-driving catalyst for enVVeno Medical.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to enVVeno Medical Corporation. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of enVVeno Medical Corporation. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company's website and the SEC website for the latest information and filings on the Company.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

FAQ

What did enVVeno Medical (NASDAQ:NVNO) present at the Virtual Investor 'Why Now' conference on August 27, 2026?

enVVeno Medical’s CEO highlighted the company’s investment opportunity and deep venous disease focus. According to enVVeno Medical, he emphasized unmet need in severe Deep Venous Insufficiency, the enVVe replacement venous valve, and recent FDA IDE approval for a pivotal U.S. trial of the device.

What is the TAVVE pivotal trial for enVVe announced by enVVeno Medical (NVNO)?

The TAVVE pivotal trial is a U.S. clinical study evaluating the enVVe venous valve system. According to enVVeno Medical, it is expected to begin in Q4 2026, enrolling about 230 patients across up to 40 U.S. clinical sites as a step toward potential regulatory approval.

When is enVVeno Medical’s TAVVE pivotal trial expected to start and how many patients will be enrolled?

The TAVVE pivotal trial is expected to commence in the fourth quarter of 2026. According to enVVeno Medical, the study aims to enroll approximately 230 patients across up to 40 U.S. clinical sites, supporting evaluation of the enVVe System in severe Deep Venous Insufficiency.

What is enVVe, the venous valve system discussed by enVVeno Medical (NVNO)?

enVVe is a non-surgical replacement bioprosthetic venous valve designed for severe Deep Venous Insufficiency. According to enVVeno Medical, the enVVe System aims to address the underlying cause of severe DVI and is being advanced through the planned TAVVE pivotal trial in the United States.

Is the Virtual Investor 'Why Now' conference presentation from enVVeno Medical available to watch on-demand?

Yes, the enVVeno Medical presentation is available as an on-demand video webcast. According to enVVeno Medical, the webcast of CEO Robert Berman’s discussion of the enVVe System, TAVVE pivotal trial plans, and investment opportunity can be accessed for later viewing by interested parties.

What does enVVeno Medical (NASDAQ:NVNO) focus on in its medical device pipeline?

enVVeno Medical focuses on bioprosthetic solutions for deep venous disease, including severe DVI. According to enVVeno Medical, it is a late clinical-stage company developing innovative tissue-based devices such as the enVVe System to improve the standard of care for deep venous conditions.